A phase 2(a), dose-blinded, block-randomized, dose and schedule selection study to evaluate the immunogenicity and safety of the recombinant plague vaccine rF1V in healthy volunteers.
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Yersinia pestis vaccine (Primary)
- Indications Plague
- Focus Pharmacodynamics
- Sponsors DynPort Vaccine Company
- 24 Mar 2008 Status changed from in progress to completed on clinicaltrials.gov.
- 17 Jul 2006 New trial record.